Methods:
To demonstrate the feasibility of improving diabetes control with the KADIS system, an experimental version of a telemedicine-based diabetes care network was established, and an international, multicenter, pilot study of 44 insulin-treated patients with type 1 and 2 diabetes was performed. Patients were recruited from five outpatient settings where they were treated by general practitioners or diabetologists. Each patient underwent CGMS monitoring under daily life conditions by a mobile monitoring team of the Karlsburg diabetes center at baseline and 3 months following participation in the KADIS advisory system and telemedicinebased diabetes care network. The current metabolic status of each patient was estimated in the form of an individualized "metabolic fingerprint." The fingerprint characterized glycemic status by KADIS-supported visualization of relationships between the monitored glucose profile and causal endogenous and exogenous factors and enabled evidence-based identification of "weak points" in glycemic control. Using KADIS-based simulations, physician recommendations were generated in the form of patient-centered decision support that enabled elimination of weak points. The analytical outcome was provided in a KADIS report that could be accessed at any time through TeleDIAB. The outcome of KADIS-based support was evaluated by comparing glycosylated hemoglobin (HbA1c) levels and 24-hour glucose profiles before and after the intervention.
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Introduction
Diabetes care is c urrently c haracterized by heterogeneous outpatient management. This has grave consequences; in approximately two-thirds of all patients, diabetes is controlled unsatisfactorily, resulting in a high prevalence of late diabetic complications, including blindness, kidney failure, and cardiovascular disease. 1 Costs of treatment are increasing dramatically, and the economic burden on health care systems is becoming unbearable.
The Diabetes Control and Complication Trial and the UK Prospective Diabetes Study (UKPDS) have convincingly shown that in type 1 and type 2 diabetes strict metabolic control by intensive treatment is effective in both decreasing the HbA1c levels and preventing long-term complications. [2] [3] [4] [5] [6] [7] Because the risk of diabetes complications is related to glycemic exposure, reflected in HbA1c levels, it is essential that euglycemia be maintained in the course of patients' daily lives. However, this requires not only monitoring HbA1c, which is a long-term indicator of glycemic control, but also determining short-term indicators of glycemic control. Conventional glucose self-monitoring provides only limited information regarding overall glycemia and postprandial hyperglycemia. Nocturnal hypoglycemic excursions often go unrecognized. The most meaningful short-term indicator of long-term prognosis is patients' integrated 24-hour glucose level, which can be accurately estimated only by continuous glucose monitoring.
In this regard, the continuous glucose monitoring system (CGMS™, Medtronic/MiniMed Inc., Northridge, CA), which measures 3-day glucose profiles, is an important advance. 7, 8 Thus far, a few studies of pediatric type 1 diabetes have reported metabolic improvement following use of the CGMS and adjustment of insulin dosage or meal schedules. [9] [10] [11] However, until the CGMS is broadly available, diabetic patients must continue to rely on selfmonitoring of blood glucose.
In light of the high frequency of long-term diabetes complications and budget deficits, better diabetes control and quality of life require a new technology that is both highly efficient and cost-effective. Another new technology supportive of individual diabetes management is TeleDIAB ® , a telemedicine-based, diabetes-related communication system, which has been developed and introduced by the Institute of Diabetes "Gerhardt Katsch" Karlsburg (IDK). 12, 18 Glucose self-monitoring may be improved with use of the Karlsburg Diabetes Management System (KADIS), a computer-based interactive management system that enables individualized evaluation of glucose profiles in association with metabolic intervention. Assessment of patients' metabolic control requires only an input of baseline characteristics, such as conventional or continuous glucose self-monitoring data, insulin dosage, meal intake, and physical activity. [13] [14] [15] Metabolic control in adult diabetic patients performing intermittent selfmonitoring of blood glucose improved within 3 months of using the KADIS. In patients with poor glycemic control, HbA1c was significantly reduced by up to 1.5% 12 and the costs of diabetes management decreased.
As KADIS and TeleDIAB both have demonstrated utility in routine clinical practice, combining these two systems with CGMS may offer a cost-effective and important advance in the management of patients with diabetes. Following the modifications of treatment and behavior as recommended by CGMS and KADIS, it might be possible to improve overall metabolic control in ambulatory diabetic patients.
The present st udy is an extension of previous locoregional studies evaluating the efficacy of the KADIS advisory system based on CGMS data. It was designed to evaluate internationally the feasibility of using KADIS in combination with TeleDIAB-based communication to improve on an individual level diabetes management in insulin-treated patients with type 1 and type 2 diabetes.
Materials and Methods
Pilot Study
Pilot study design
This multicenter, open-label cohort study was performed between February 2004 and March 2006 and investigated the application of KADIS combined with TeleDIAB among insulin-treated diabetes patients who underwent two 72-hour periods of continuous glucose monitoring with CGMS 3 months apart.
The pilot study comprised six steps: (1) prestudy examination; (2) a 3-month run-in phase without KADIS and TeleDIAB; (3) the first CGMS trial including HbA1c estimation and documentation of self-control data, generation of patient-centered KADIS reports, and delivery of reports to study physicians; (4) a 3-month observation period in which KADIS and TeleDIAB support was implemented by the study patients under daily life conditions as recommended by their physicians; (5) a second CGMS trial, including HbA1c estimation and documentation of self-control data; and (6) final data analysis and evaluation.
Pilot study procedure
Before implementation of KADIS, an initial CGMS trial was performed. Together with the measured HbA1c levels at baseline, results of the first trial represented the metabolic outcome during the 3 months before application of KADIS. These data were used to estimate each patient's metabolic fingerprint. Subsequently, the patient-focused KADIS report was generated and provided to physicians. Patients were advised by their physicians to adhere to the KADIS-based recommendations during the next 3 months. Thereafter, a second 72-hour CGMS trial was performed, and measurement of HbA1c was repeated.
Prestudy examinations were conducted by physicians in the five participating outpatient settings.
Seventy-two-hour CGMS monitoring
CGMS monitoring commenced after breakfast. CGMS sensors (Medtronic, Northridge, CA) were inserted into the subcutaneous abdominal fat tissue and calibrated against glucometer readings according to the standard Medtronic operating guidelines. For calibration purposes, patients were asked to enter at least four glucometer readings per day into the CGMS monitor. After 72 hours, recorded data were downloaded using Medtronic/MiniMed Solution Software (Medtronic).
Recorded profiles with less than three glucometer entries (calibrations) per day were disregarded. Patients were also asked to log self-control data [insulin administration, intake of oral antidiabetic drugs (OAD), further therapy, food consumption, and physical exercise] and to record any events such as hypoglycemic symptoms that could potentially affect glucose control.
Patients
Study patients were selected randomly by the participating general practitioners (GPs)/diabetologists in the catchment areas of their outpatient settings according to predefined inclusion and exclusion criteria. All patients underwent a prestudy examination; after examination, the patients were included if the examining physician certified that to his/her knowledge all inclusion criteria were met, no exclusion criteria were present, and the patient was suitable for the study. Eligibility criteria were insulin-treated type 1 or type 2 diabetes, diabetes duration >2 years, age >18 years, male or female gender, and written informed consent. Exclusion criteria were preceding ketotic acidosis; existing acute hepatic, renal, gastrointestinal, or inflammatory disease; lactation or pregnancy; and lack of willingness or ability to follow written or verbal instructions. Exclusion criteria were chosen to ensure exclusion of patients with specific risks for metabolic decompensation.
At the prestudy examination, each subject was given a screening number that was replaced by an internal subject identification number after enrollment. At any time, subjects could be withdrawn from the study at their own request or based on the clinical judgment of the participating physician. Reasons for withdrawal included lack of tolerability, intercurrent disease, noncompliance with the study procedure, or withdrawal of consent.
All participants underwent an informed consent process, where they had an opportunity to ask any questions and obtain any information regarding the study procedure or risk-benefit relationship. The study was approved by the ethical review boards at the University of Greifswald, Germany, and the Ministry of Health of the United Arab Emirates. It was performed according to the rules governing medical procedures in the European Community and the Declaration of Helsinki.
KADIS-and TeleDIAB-Based Services
KADIS is an interactive computer program that offers recommendations for individual therapeutic adjustments in type 1 and type 2 diabetes. It is based on the Karlsburg model for description and assessment of glucose-insulin metabolism. The model was developed during several decades of intense basic and clinical research at the IDK. 14 Based on entered self-control and therapeutic data, KADIS identifies the patient's individual metabolic status and generates a digital in silico metabolic profile. This enables prediction for a given patient daily glucose profile by computer-assisted simulation of the effects of therapeutic adjustments, implying treatment with insulin and/or antidiabetic drugs, physical activity, and meal consumption. Simulation results are summarized and issued in a KADIS report and provided to doctors in terms of patient-centered decision support.
KADIS was used for several purposes. First, it provided estimations of characteristic glucose patterns reflecting the 24-hour glucose profile of an individual patient in relation to his or her current metabolic status. Patient metabolic status was determined by 24-hour action profiles of endogenous and/or exogenous insulin, OAD, and physical activity and 24-hour profiles of carbohydrate absorption rates in relation to the individual 24-hour glucose profiles. This characteristic pattern is an individual indicator of a patient's glycemic control, or the metabolic fingerprint (Figure 1) , provided the patient undergoes continuous long-term glucose measurement using a CGMS or other monitoring system. Second, KADIS was used to perform weak-point analysis of glycemic control based on the metabolic fingerprint. Third, KADIS-based simulations of changes in insulin application, dosage, and timing of oral antidiabetic drugs, meals, and physical activity were evaluated and visualized according to the guidelines of the International Diabetes Federation. Results were issued as a KADIS report and used to generate patientcentered decision support for the physicians to overcome identified weak points in the daily diabetes management of their patients. The KADIS report, together with appropriate physician advice, could be retrieved at any time via TeleDIAB.
The telemedicine-based communication platform TeleDIAB provided the study patients and doctors with 24-hour access (via protected, individual data channels) to the metabolic fingerprints and KADIS reports (only doctors) as well as competent counseling to interpret and apply the KADIS-based recommendations appropriately.
Telemedicine-Based Diabetes Care Network
The diabetes care network ( were generated by DCC personnel that contacted and visited doctors and their patients every 2-4 weeks.
All physicians in the diabetes care network had continuous access to DIROC counseling, information, and services for application of the patient-centered KADIS reports (Figure 2) as a "second opinion" to optimize glycemic control in their patients (Figure 2) .
The IDK coordinated all research and development activities within the telemedicine-based diabetes care network. The DCC administrated KADIS and TeleDIAB and oversaw the activities of the administrative network. Administrative activities included contacting patients and providing reminder or recall services in close cooperation with the DIROC and the physicians of the diabetes care network.
DIROC provided medical counseling and care services, including patient education and staff training. DIROC personnel performed the CGMS trails using mobile TeleDIAB monitors in close proximity to patients' homes and educated physicians and their patients on how to interpret the patient-centered metabolic fingerprints.
Data Processing and Statistical Analysis
Comparison of the outcome of metabolic control before and after KADIS application was used to evaluate the outcome of KADIS implementation in diabetes outpatient care.
Primary outcomes were HbA1c and mean blood glucose level from the 24-hour glucose profile. Secondary measures were the duration of hypoglycemic and hyperglycemic excursions (hours/day) in the 24-hour glucose profiles, daily insulin supply (IU/day), and carbohydrate (CHO) intake, which was expressed in bread exchange units (BU/day; 1 BU = 10-12 g CHO).
CGMS data were presented as 24-hour glucose profiles showing three individual sensor days and a mean 24-hour glucose profile calculated from the three subsequently monitored CGMS sensor profiles. The area of normoglycemia, defined as the range between 8.9 and 4.4 mmol/liter, was highlighted, allowing visual and statistically based judgment of hypoglycemic and hyperglycemic episodes (Figures 1 and 3) . To evaluate the proposed dependency of the outcome on HbA1c levels at the beginning of the study [HbA1c(0)], study patients were subdivided into the following HbA1c(0) categories: <7.0, 7.0-8.0, 8.0-9.0, and >9.0%. Blood pressure, heart rate, and adverse events were analyzed descriptively. (1) and medical counseling regarding the KADIS support (5); the DCC, which oversees the telemedicine-based communication platform TeleDIAB; and KADIS, which generates the patient-specific metabolic fingerprint (2) and provides KADIS-based decision support (KADIS report); (3) and physicians in outpatient settings who apply KADIS-based decision support to patients (4). Analysis of the primary and secondary variables included all per-protocol subjects: all patients who underwent the study procedures, had available measurements of the primary variable in the afore-defined periods of the study, and lacked a major protocol violation, including violation of entry criteria. The necessary cohort size was assessed using data on routine metabolic control and previous continuous glucose monitoring. It was determined that to detect changes in HbA1c in the range of 0.2-1.0% that achieved statistical significance, 6-10 patients were needed. To evaluate patients' continuum of glycemic control, 1.5-2 interpretable days of sensor recording (i.e., days with at least three to four paired sensor readings) were necessary. Thus, 6-10 patients should be sufficient to obtain solid data on continuous glucose monitoring. We estimated from previous data that this number of patients would provide sufficient power to detect correlation coefficients of approximately 0.40 at a 5% level of significance.
All statistical analyses were performed using SPSS (Chicago, IL). Results are given as the mean ± SEM for normally distributed parameters or as the median and interquartile range for insulin dose, carbohydrate intake, hypoglycemia, and hyperglycemia.
Differences in the outcome of HbA1c for the first and second CGMS trials are presented as ∆HbA1c, the mean change in the individual values with 95% confidence intervals. Comparisons between groups were calculated using the unpaired Student's t test. Multiple regression analysis with stepwise forward selection was performed to identify variables related to ∆HbA1c. Independent variables were HbA1c(0), physician specialty (GP or diabetologist), type of diabetes, sex, age, body mass index (BMI), and type of therapeutic support (with or without KADIS-based decision support). Statistical significance was set to p = 0.05.
Results
Patient Characteristics
Forty-four patients passed the prestudy examination and were enrolled. Seven study patients had an incomplete CGMS trial. One of the two HbA1c values was missing for two patients, and one patient did not follow the KADIS-based recommendations. None of these patients withdrew written consent. Basically, there were no important differences in demographics of the rejected patients and the remainder of the patients. Nevertheless, because of incomplete data acquisition, these patients were excluded from the final data analysis.
The characteristics of the 34 study patients whose data were included in the analysis are presented in Table 1 . Fifteen of these patients had type 1 diabetes, and 19 had type 2 diabetes. Nearly equal numbers of study patients were treated by diabetes specialists (18) and GPs (16) . The mean age of the study population was 44.6 years, with mean disease duration of 11.5 years. The mean BMI was 31.0 kg/m 2 , indicating that patients were, on average, moderately overweight. 
Outcomes
To illustrate typical results obtained before and after application of KADIS-based decision support, Figure 3 shows an example of CGMS and mean 24-hour glucose profiles for a patient with type 2 diabetes. Regarding the entire cohort, after 3 months of KADIS-based decision support there was an overall reduction in HbA1c (∆HbA1c) of 0.62 ± 0.14% (p < 0.01; Table 2 ; Figure 6 ). Reduction of HbA1c was accompanied by a decrease in the mean blood glucose level (MBG) calculated from the 24-hour glucose profile from 9.08 ± 0.34 to 7.86 ± 0.28 mmol/liter (p < 0.01). Improved glycemic control was also apparent in the significant reduction of the duration of hyperglycemia from 8.2 to 5.1 hours/day (p < 0.05). Neither insulin dosing (IU/day) nor carbohydrate intake (BU/day) was changed. In addition, serious hypoglycemic episodes were not reported by the patients ( Table 2) .
Multiple regression analysis demonstrated a highly significant relationship between HbA1c outcome and HbA1c(0) (Figure 6) . The effect of KADIS-based decision support was greatest (1.22% reduction) for the group with HbA1c(0) >9.0% and lowest (0.12% reduction) for the group with HbA1c(0) between 6.0 and 7.0%.
KADIS-driven reductions in HbA1c, mean 24-hour glucose levels, and duration of hyperglycemia were related to the type of diabetes (Figure 4) . KADIS-based decision support was slightly more effective for patients with type 1 diabetes versus type 2 diabetes (∆HbA1c: -0.79% vs -0.48%; Salzsieder Outcomes were also dependent on the outpatient treatment setting. KADIS-based decision support was more effective for patients treated by GPs than for patients treated by diabetes specialists (Figure 5) . The reduction of HbA1c was 1.02% for patients treated by GPs and 0.25% for patients treated by diabetologists. The MBG calculated from the 24-hour glucose profile was He checked his blood glucose two to three times daily. The sensor profile showed throughout 3 days of glucose monitoring profound, long-lasting hyperglycemia after breakfast and hyperglycemic episodes after lunch. KADIS-based analysis recommended dividing the total insulin dose (28 IU, Novo Mix 30) into two injections, changing timing for the first insulin injection of 14 IU from 10:00 to 8:00 PM and setting timing for the second 14 IU to 10:00 AM, and changing meal intake from three main meals to four smaller meals, with the same total of 13 BU. After therapy adjustment according to the recommendations, the modal daytime sensor profile showed near euglycemia with only one hyperglycemic episode. The HbA1c level decreased from 7.8 to 6.9% during follow-up. The patient reported significant improvements in well-being and increased efforts to manage his diabetes. 
Discussion
We have reported an evaluation of an intervention combining use of the KADIS advisory system and a telemedicine-based diabetes care network in outpatient settings. The question we sought to address was whether physicians (GPs and diabetes specialist) would achieve better metabolic control of their diabetic patients when provided with KADIS-based decision support compared to when lacking this support. Results show that telemedicine-based application of KADIS in combination with CGMS can improve glycemic control in both type 1 and type 2 diabetes.
The recommendations provided to physicians by KADIS are focused on insulin dosage, time of application, food intake, physical exercise, and behavioral advice. In addition, KADIS has the unique abilities to identify each patient's individual metabolic status in terms of a metabolic fingerprint and to generate patient-centered decision support in the form of computer-assisted simulation procedures. These abilities lend it great potential to improve diabetes care.
Indeed, physicians using KADIS-based decision support achieved improved metabolic control for their patients within 3 months. Remarkably, a 0.62% reduction of HbA1c and a prolongation of normoglycemia by approximately 3 hours/day were achieved without increased risk of hypoglycemia. UKPDS showed that each 1% reduction in HbA1c is associated with an overall 21% reduction in risk of any end point related to diabetes, thus 21% for deaths related to diabetes, 14% for myocardial infarction, and 37% for microvascular complications. 16, 17 In light of this, our findings suggest great potential of KADIS-based decision support to decrease the risk of development of diabetes-related complications.
The reduction of HbA1c following KADIS-based decision support is consistent with earlier studies in insulin-treated diabetes patients in Germany and the United Arab Emirates, showing a reduction in HbA1c from a baseline level >9 to 6.7% (2.3% reduction) within 21 months 12,18 and to 7.8% (1.2% reduction) within 6 months (unpublished data). Similar to our findings, users of the Diabetes Advisory System (DIAS) achieved improved metabolic control. A meta-analysis of DIAS studies involving a total of 82 patients revealed a HbA1c reduction of 1.2%. 19 Also, after a 6-month application of a blood glucose prediction engine for managing medication doses, HbA1c decreased significantly from 9.7 to 7.9%. 20 Ludvigsson and Hanas 21 reported a HbA1c reduction from 7.70 to 7.31% in type 1 diabetes patients after 3 months of using CGMS-based decision support. Chico and colleagues 22 observed a HbA1c reduction from 8.3 to 7.5% in patients with type 1 and 2 diabetes using CGMS.
The visual nature of the CGMS profiles helped adults and children with diabetes identify hyperglycemia and hypoglycemia, resulting in improved HbA1c levels. 8, 23 However, CGMS was not effective in patients with nearnormal baseline HbA1c (6.5-7.5%), whereas the use of CGMS and KADIS decision support reduced HbA1c by 0.2-1.0% (unpublished data). Apparently, CGMS curves provide limited information for patients in this category, whereas KADIS-based decision support is more useful, containing detailed recommendations for improving metabolic control based on the hormonal and metabolic processes determined individually for the patient.
KADIS-based decision support might have dual potential for improving metabolic control and preventing the upwards drift in HbA1c that is associated with diabetes progression. Indeed, among patients with baseline HbA1c below 7.0%, HbA1c was maintained at nearly the same level with KADIS-based decision support. Thus, KADIS may provide a long-term clinical benefit for patients with near-target HbA1c by preventing diabetes-associated complications. We also found that diabetes patients with HbA1c above 7.0% developed better metabolic control when using KADIS-based decision support, suggestive of a short-term benefit of KADIS. This finding underlines that the positive effect of KADIS-based decision support on patient-centered diabetes care is independent of baseline HbA1c levels.
There is a clear relationship between glycemic control, reflected by HbA1c, and progression of microvascular complications in type 1 and type 2 diabetes. 24 The mean HbA1c for our patients was 8.19%, suggesting a high risk of complications 25, 26 and need for metabolic improvement. 27 The evidence-based Global Guideline for Type 2 Diabetes developed by the International Diabetes Federation in 2005 recommends maintenance of HbA1c levels below 6.5% in insulin-treated diabetes patients to minimize the risk of complications. 28 At the beginning of our study, only 11.8% of the patients met this goal, but 3 months after application of KADIS-based decision support the percentage increased to 29.4%. This clearly demonstrates the usefulness of KADIS-based decision support.
Together, modern information and communication technologies and the development of care-providing services will ultimately change the patient's role. The hierarchy between patient and primary care physician will dissolve as the patient-physician relationship becomes more of a partnership, wherein the physician empowers the patient to achieve glycemic targets and enables the patient, within a certain frame, to make his or her own therapeutic decisions. Such guidance is a central component of the telemedicine-based diabetes care network with KADIS-based decision support presented in this study. Interactive generation of personalized therapeutic strategies is a feature unique to KADIS. In contrast to other models of glucose and insulin metabolism, [29] [30] [31] [32] KADIS enables identification of individual blood glucose profiles and simulation of the effects of lifestyle and therapeutic modifications, including insulin doses, exercise, and food intake.
Recent advances in information and communication technology allow the design and testing of new models of diabetes management t hat can assist patients regardless of their distance from the health care provider. Our telemedicine-based diabetes care network comprises five main components: a DCC that generates the patient-specific metabolic fingerprint and patient-centered decision support; TeleDIAB, which communicates data via the Internet; the outpatient DIROC u n it t hat perfor m s cont i nuous glucose monitoring under daily life conditions and provides 24hour medical counseling; and physicians in outpatient settings who are responsible for diabetes care. The advantage of this diabetes care network is the addition of individualized advice to approaches such as Webbased electronic medical records and messaging systems, computer telephony integration service, home-based smart modems, and specialized software modules for automated data analysis. [33] [34] [35] [36] KADIS is the heart of the network.
The ability to provide advice regarding treatment of individual patients distinguishes our network from telecare approaches and provides added benefits. For example, Pro-Active Call Center Treatment Support for improvement of glucose control in type 2 diabetes reduced the HbA1c by 0.49% from a baseline level of more than 7%. 37 Patients in this study received lifestyle advice and drug treatment and were kept informed permanently by phone according to changes in the HbA1c level. In another study, where telecare included glucometer transmission with feedback, type 1 diabetes patients with inadequate glycemic control underwent improvement. 38 However, the benefit of telecare is restricted to patients with type 1 diabetes with intensified insulin therapy. A metaanalysis of seven randomized trials in type 1 diabetes revealed a 0.4% difference in the mean change in HbA1c from baseline between telecare and control groups. 38 In the present study in our type 1 diabetes subgroup, we demonstrated a mean reduction of HbA1c of 0.79% and a reduction of MBG of 1.6 mmol/liter within 3 months. This indicates that the telemedicine-based diabetes care network has great potential for preventing diabetes complications. Evidence shows that a 1.0% reduction in HbA1c is associated with a 37% reduction in microvascular complications. 39 The benefit of lowering blood glucose, including reducing the risk of complications to the eyes, heart, kidneys, and feet, is well established.
Although the development and introduction of continuous glucose monitoring systems represent a milestone in diabetes care, 8 for the majority of patients, improvements in glycemic control have not met expectations thus far. The main reason is that although 24-hour glucose profiles can be measured continuously, the cause of glucose excursions remains largely unknown. This problem could be eliminated by application of CGMS in combination with KADIS-based decision support, wherein a personalized metabolic fingerprint is assessed and used to predict glycemic control under various therapeutic regimens, which forms the basis for patientcentered decision support. CGMS and KADIS could act synergistically in improving diabetes care. KADIS overcomes the apparent deficits in CGMS decision support by incorporating reliable data instead of interpretations and suggestions. Its ability to simulate the individual outcome of future therapy has considerable potential and may allow KADIS-based decision support to become a powerful tool in diabetes care and management.
Our results demonstrate sig n ificant advantages of combining KADIS-based decision support with TeleDIAB and CGMS in outpatient diabetes care to Salzsieder visualize patients' current metabolic status, develop a reproducible weak-point analysis of actual glycemic control based on pathophysiology, and provide evidencebased therapeutic recommendations based on patients' daily life conditions, age, and physical capacity. To the patient's benefit, optimal therapeutic adjustments can be applied immediately without wasteful periods of trialand-error identification of appropriate patient-centered treatment.
In conclusion, KADIS-based decision support, in combination with CGMS and a telemedicine-based diabetes care network, has great potential to become an efficient tool for diabetes care and management. Future studies with larger numbers of patients and extended observation periods should validate this approach for general clinical application.
